You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Quantum Similarity Approach for the Discovery of Anti-Trypanosome Drug Leads

    SBC: GRADIENT BIOMODELING, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Human African trypanosomiasis (HAT) is an infectious disease with a large global health burden occurring primarily in Central and Eastern Africa. HAT is 100% fatal if untreated and the current drug therapies suffer frompoor safety profiles, difficult treatment regimens, limited effectiveness, and high costs. Furthermore, drugs that cross the blood brain barrier ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Multiplexed Ovarian Cancer Microfluidic Tissue Microarray

    SBC: Carterra, Inc.            Topic: NCI

    Project Summary We propose an instrument system for automated, multiplexed cell- and tissue-based experiments (i.e. tissue microarrays) called the Microfluidic Flow Cell Array (MFCA). The MFCA consists of a microfluidic flow cell array integrated with an inverted fluorescent microscope, allowing the observation of 48 flow chambers simultaneously or an individual chamber at higher magnification. Th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. The Development of Novel Inhibitors of BCL2 Gene Expression as Anticancer Therape

    SBC: TETRAGENE, LLC            Topic: NCI

    Project Summary Evasion of apoptosis is a hallmark of cancer and is associated with oncogenesis, tumor maintenance, and resistance to conventional chemotherapy. BCL-2 was the first identified anti-apoptotic factor and is a member of the BCL-2 family of proteins that cooperate in the regulation of programmed cell death. BCL-2 plays a dominant role in the survival of multiple lymphoid malignancies a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting ether lipid biosynthesis for disease

    SBC: ECHELON BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancer is a significant health burden in the US and across the globe, representing the second leading cause of death in the US. Cancer cells have metabolic pathways that are altered significantly compared to normal cells. As a result, the pathways involved (lipid biosynthesis for example) are considered excellent targets for therapeutic intervention. The levels ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis

    SBC: GLYCOMIRA, LLC            Topic: NIDCR

    DESCRIPTION (provided by applicant): GlycoMira Therapeutics has developed safe and effective anti-inflammatory glycosaminoglycan derivatives and proposes to test the feasibility of using its lead compound to treat or prevent oral mucositis. Mucositis is acommon and debilitating complication of cancer treatment. Cancer patients undergoing radiation or chemotherapy often develop this painful inflam ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Patient Breath Simulator for Capnometer Performance Verification

    SBC: WITTING INNOVATION LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Capnometers can fail in a number of ways that are not detectable using current static calibration testing procedures. These failures could include leaks in the sample line, a weak sample pump, inadequate dynamic response, flow restriction and flow obstruction. Failure of a capnometer during critical care procedures such as sedation and anesthesia can be life th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. HT Label-Free Screening and Kinetic Analysis of Small Molecules and Biologics

    SBC: Carterra, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Real-time label-free technologies such as surface plasmon resonance biosensors provide high-resolution information about the kinetics, affinity, stoichiometry, activity, and specificity, of two (or more) binding partners. While the application f biosensors is well established, current instrumentation has limited sampling throughput. Screens of even a fairly sma ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Hepatitis C Virus RNA-Targeted Therapeutics

    SBC: VIOGEN BIOSCIENCES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a significant human health issue, accounting for 50% of liver transplants in the US, with approximately 170 million persons infected worldwide. The current standard of care therapy of PEGylated-interferon and ribavirin is effective in only about 50% of patients, with severe side effects and contraindications limiting patient ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Selective activation of the vagus nerve as an improved therapy for heart failure

    SBC: BLACKROCK MICROSYSTEMS, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The goal of the proposed project is to alleviate the enormous public health burden of heart failure. Heart failure leads to significant morbidity and mortality, affects almost five million Americans, and results in morethan 35 billion dollars in annual healthcare costs. Current pharmacological and surgical treatments are only moderately effective and can have s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. IGF::OT::IGF-- Biomarkers for Alcohol and ALD

    SBC: ECHELON BIOSCIENCES, INC.            Topic: NIAAA

    This contract addresses the need for reliable and accurate biomarkers of alcohol consumption, initially in response to a National Institute on Alcohol Abuse and Alcoholism (NIAAA)-initiated Small Business Innovation Research (SBIR) contract topic on Biomarkers for Alcohol-induced Disorders. The goals of this contract are to advance the usefulness of phosphatidylethanol (PEth), an alcohol metabolit ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government